Kangenbei plans to transfer 25.3359% equity of Jiahe bio with RMB 953 million

On July 27, Kangenbei announced that it planned to invest 25.3359% of its equity in Jiahe biopharmaceutical Co., Ltd (corresponding to 13% of the registered capital of Jiahe biopharmaceutical Co., Ltd, RMB 4093771) was transferred to HH CT Holdings Limited (hereinafter referred to as "HH CT"), a wholly-owned subsidiary of jhbp (CY) Holdings Limited (hereinafter referred to as "jhbp (CY)") This transaction is to further promote the equity restructuring of Jiahe bio's overseas listing, so as to realize that the company ultimately holds 25.3359% equity equal to that of Jiahe bio currently held by the company through jhbp (CY) And signed the equity transfer agreement on July 26, 2019 Founded in December 2007, Jiahe biology is a wholly foreign-owned enterprise invested by Wison holding (Group) Co., Ltd with a registered capital of US $10 million, which was approved by the Shanghai Municipal People's government shwz [2007] No 4136 document Jiahe biological's business scope covers the research and development of monoclonal antibodies and biological products (except the development and application of human stem cells, gene diagnosis and treatment technology), as well as the research and development of instruments, equipment and reagents related to monoclonal antibodies and biological products, the transfer of its own technology, and the provision of relevant technical consultation and technical services, engaged in instruments, instruments, mechanical equipment Wholesale, import and export of pharmaceutical equipment and pharmaceutical intermediates, commission agency (excluding auction), and provide relevant supporting services According to the announcement, there are 10 McAb products that are the focus of Jiahe bio's project at present, including McAb biological analogues and McAb innovative drugs Nine of the products have entered the clinical trial stage, and the indications cover three major fields: tumor, autoimmune disease and metabolic disease In addition to its own development, Jiahe biology has also carried out a number of domestic and foreign cooperation through cooperative development and authorization At present, the products in phase III clinical trial in China are: anti HER2 humanized monoclonal antibody (trade name of similar drug: Herceptin), infliximab biological similar drug (trade name of original research drug: Lei Ke, REMICADE) and bevacizumab biological similar drug (trade name of original research drug: Avastin); the products in phase II clinical trial are: genomab Injection (PD-1) The R & D pipeline of Jiahe biology is shown in the following table: